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Abstract
Adjuvant systemic chemotherapy (CTx) is widely administered in patients with colorectal liver metastases (CRLM). Histo-
pathological growth patterns (HGPs) are an independent prognostic factor for survival after complete resection. This study 
evaluates whether HGPs can predict the effectiveness of adjuvant CTx in patients with resected CRLM. Two main types of 
HGPs can be distinguished; the desmoplastic type and the non-desmoplastic type. Uni- and multivariable analyses for overall 
survival (OS) and disease-free survival (DFS) were performed, in both patients treated with and without preoperative chemo-
therapy. A total of 1236 patients from two tertiary centers (Memorial Sloan Kettering Cancer Center, New York, USA; Eras-
mus MC Cancer Institute, Rotterdam, The Netherlands) were included (period 2000–2016). A total of 656 patients (53.1%) 
patients received preoperative chemotherapy. Adjuvant CTx was only associated with a superior OS in non-desmoplastic 
patients that had not been pretreated (adjusted hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.37–0.73, p < 0.001), 
and not in desmoplastic patients (adjusted HR 1.78, 95% CI 0.75–4.21, p = 0.19). In pretreated patients no significant effect 
of adjuvant CTx was observed, neither in the desmoplastic group (adjusted HR 0.83, 95% CI 0.49–1.42, p = 0.50) nor in 
the non-desmoplastic group (adjusted HR 0.96, 95% CI 0.71–1.29, p = 0.79). Similar results were found for DFS, with a 
superior DFS in non-desmoplastic patients treated with adjuvant CTx (HR 0.71, 95% CI 0.55–0.93, p < 0.001) that were not 
pretreated. Adjuvant CTx seems to improve OS and DFS after resection of non-desmoplastic CRLM. However, this effect 
was only observed in patients that were not treated with chemotherapy. 
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Introduction
Pre- and or postoperative systemic chemotherapy is often 
administered in patients with potentially resectable colo-
rectal liver metastases (CRLM). The effectiveness has been 
investigated in randomized controlled trials [1–4]. The long-
term follow-up of a phase III trial demonstrated a superior 
early progression-free survival (PFS) for patients treated 
with perioperative FOLFOX. However, there was no differ-
ence in overall survival (OS) with long term follow-up [5].
Retrospective studies have suggested that the effective-
ness of systemic chemotherapy may depend on the extent 
of disease or factors associated with OS. Potentially posi-
tive associations of perioperative systemic chemotherapy 
and OS were seen in populations with a high clinical risk 
score (CRS), or elevated preoperative carcinoembryonic 
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antigen (CEA) levels [6–8]. In order to adequately identify 
subgroups that benefit from adjuvant chemotherapy (CTx) 
after resection of CRLM, biomarkers that reflect actual 
tumor biology are needed.
Recent studies have suggested that the histopathological 
growth patterns (HGPs) of CRLM, obtained from hematoxy-
lin and eosin (H&E) stained tissue sections after resection, 
are able to identify patients with an unfavorable tumor biol-
ogy [9–11]. Two main types of HGPs can be distinguished; 
a desmoplastic type (dHGP) and a non-desmoplastic type 
(non-dHGP) [10, 12]. The dHGP is driven by angiogenesis 
and elevated infiltration of immune cells is observed. Mor-
phologically these tumors are characterized by a desmoplas-
tic rim surrounding the tumor border. In non-dHGP CRLM, 
the tumor cells replace the liver parenchyma by using pre-
existing liver vessels for blood supply (i.e. vessel co-option) 
instead of angiogenesis [11, 12]. Non-dHGP has been 
associated with a worse prognosis for patients undergoing 
resection of CRLM in multiple studies [10, 13, 14]. A large 
cohort study suggested that this effect was predominantly 
found in patients that were not pretreated with chemotherapy 
prior to CRLM resection [10] (Fig. 1).
As HGPs reflect biological processes associated with 
tumor growth, this factor may be used to assess the effect 
of adjuvant CTx. This multicenter study aimed to evaluate 
if HGPs can be used to predict the effectiveness of adjuvant 
CTx after resection of CRLM.
Methods
Study population
All consecutive patients who underwent a complete resec-
tion of CRLM from 2000 to 2016 at Memorial Sloan Ket-
tering Cancer Center (MSKCC, New York, United States) 
and at the Erasmus MC Cancer Institute (Erasmus MC, 
Rotterdam, The Netherlands), were evaluated for inclu-
sion. A total of 2608 consecutive patients were evaluated 
for inclusion. Patients were excluded from analysis for the 
following reasons: adjuvant hepatic artery infusion pump 
chemotherapy, R2 resection, no resection of primary tumor, 
extrahepatic disease prior to or at time of liver resection, 
and H&E stained tissue sections that were not suitable for 
scoring HGPs. H&E tissue sections were considered non-
suitable if there was less than a 20% of the expected tumor-
liver interface, showed poor tissue preservation or when 
viable tumor tissue was absent [13]. In total 1236 (47.4%) 
were eligible for inclusion (Fig. 2).
Fig. 1  H&E images of the HGP types. H&E tissue section. a Desmo-
plastic HGP; b replacement HGP; c pushing HGP
Fig. 2  Study flowchart. HAIP: hepatic arterial infusion pump, H&E: 
hematoxylin and eosin
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HGP characterization
HGPs were evaluated according to international guidelines 
[13]. In order to determine HGP type, all available H&E 
stained tissue sections off all available CRLM were evalu-
ated using light microscopy for each patient. The entire 
interface between tumor and adjacent liver tissue was evalu-
ated for the type of HGP and the proportion of each HGP 
was scored using percentages. Average HGP percentages 
were calculated per metastasis and per patient (in case of 
multiple CRLM). This method has been validated previ-
ously, demonstrating a 95% within CRLM concordance (in 
case of multiple H&E slides) and a 90% between metastases 
concordance (in case of multiple CRLM in one patient) [14]. 
Patients were classified in two groups: dHGP if all available 
slides showed a 100% desmoplastic interface and non-dHGP 
if a replacement or pushing type HGP was found on one 
or more slides [10]. Non-dHGP CRLM represent a mix of 
different interfaces with a varying degree of desmoplastic, 
replacement, and pushing type HGPs. Pushing type HGP 
CRLM are rare and are vascularized by angiogenensis in the 
absence of a desmoplastic stromal rim [11, 12].
Timing of chemotherapy
In MSKCC, most patients received pre- and/or postoperative 
(i.e. adjuvant) chemotherapy. In the Erasmus MC cohort, 
preoperative chemotherapy was regularly administered in 
referring hospitals or in patients with borderline resectable 
CRLM. Patients with upfront resectable CRLM were not 
treated with preoperative chemotherapy at Erasmus MC. 
Adjuvant chemotherapy is not the standard of care after 
resection of CRLM according to the Dutch guidelines. All 
analyses were performed separately for patients treated with 
and without preoperative chemotherapy according to the 
findings by Galjart et al., demonstrating limited prognostic 
value of HGPs in pretreated patients [10].
Definitions
Clinicopathological data and postoperative treatment data 
were available from prospectively maintained databases. 
Synchronous CRLM were defined as detected within 
3 months after resection of the primary tumor. Number 
and size of CRLM were derived from pathology reports. 
Any lesions treated with ablative therapies (Radio Fre-
quency Ablation or Microwave Ablation) were added to 
the total number of CRLM treated. The clinical risk score 
(CRS) was calculated by assigning one point for the pres-
ence of each of the five components: node positive primary 
tumor, disease-free interval between resection primary and 
diagnosis of CRLM less than 12 months, more than one 
CRLM, size of largest CRLM above 5 cm, and preoperative 
serum carcinoembryonic antigen (CEA) level of more than 
200 µg/L [8]. The CRS was subdivided into low-risk (0–2 
points) and high-risk (3–5 points). A positive resection 
margin was defined as the presence of viable tumor at the 
resection margin. Preoperative chemotherapy was defined 
as any chemotherapy administered within six months before 
liver resection. Adjuvant chemotherapy was defined as any 
systemic chemotherapy administered within six months 
after liver resection as long as it was not used for recurrent 
disease.
Statistical analysis
Differences between groups in baseline characteristics were 
evaluated using the Chi-square test for categorical variables 
and the Mann–Whitney U-test for continuous variables. 
Median follow-up time for survivors was estimated using 
the reversed Kaplan–Meier method. Complete case analy-
sis for the regression analyses was performed. Survival was 
estimated by the Kaplan–Meier method and groups were 
compared using the log-rank test. OS was defined from 
the date of CRLM resection until the date of last follow-
up or death. Disease-free survival (DFS) was defined from 
the date of CRLM resection until the date of recurrence, 
last follow-up or death. Uni- and multivariable analyses of 
OS and DFS were performed with Cox proportional haz-
ard modeling. Results were reported as hazard ratios (HR) 
with 95% confidence intervals (CI). A p-value of less than 
0.05 was considered statistically significant. Analyses were 
performed using SPSS (IBM Corp, version 24, Armonk, 
NY) and RStudio (RStudio, version 1.0.153, Boston, MA; 
survival package).
Results
Patient characteristics
A comparison at baseline was made between patients treated 
with and without adjuvant CTx (Table 1). Patients that 
were not pretreated who received adjuvant CTx had more 
common left-sided primary tumors (50.0% versus 40.4%, 
p < 0.001). Patients that were pretreated who received adju-
vant CTx had more advanced T-stage (pT3-4) primaries 
(91.5% versus 84.6%, p = 0.03).
The median follow-up time for survivors was 83.0 months 
(IQR 51–118 months), and 720 patients (54.8%) died dur-
ing follow-up. The 5-year OS for patients from MSKCC 
not treated with adjuvant CTx was 46.9% (95% CI 
38.8%–56.7%) compared to 46.5% (95% CI 41.1%–52.6%) 
for patients from Erasmus MC (p = 0.83).
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Table 1  Baseline characteristics (n = 1236)
Not pretreated Pretreated
All patients No adjuvant 
CTx
Adjuvant CTx P value All patients No adjuvant 
CTx
Adjuvant CTx P value
Sample size 580 (100%) 451 (77.8%) 129 (21.2%) – 656 (100%) 488 (74.4%) 168 (25.6%)
Age (median, 
IQR)
66.0 (58.0–
74.0)
66.0 (59.0–
74.0)
66.0 (55.0–
72.0)
0.84 62.0 (53.0–
69.0)
63.0 (54.0–
70.0)
58.0 (49.0–
66.0)
0.05
Gender 0.08 0.27
 Male 358 (61.7%) 287 (63.6%) 71 (55.0%) 410 (62.5%) 311 (63.7%) 99 (58.9%)
 Female 222 (38.3%) 164 (36.4%) 58 (45.0%) 246 (37.5%) 177 (36.3%) 69 (41.1%)
Center  < 0.001  < 0.001
 MSKCC 203 (35.0%) 76 (16.9%) 127 (98.4%) 352 (53.7%) 188 (38.5%) 164 (97.6%)
 Erasmus MC 377 (65.0%) 375 (83.1%) 2 (1.6%) 304 (46.3%) 300 (61.5%) 4 (2.4%)
Colorectal 
cancer
 Primary tumor 
location
 < 0.001 0.33
  Right-sided 134 (23.8%) 91 (20.8%) 43 (3.7%) 143 (22.5%) 104 (21.7%) 39 (25.0%)
  Left-sided 239 (42.5%) 177 (40.4%) 62 (50.0%) 305 (48.0%) 227 (47.3%) 305 (48.0%)
  Rectum 189 (33.6%) 170 (38.8%) 19 (15.3%) 188 (29.6%) 149 931.0%) 188 (29.6%)
  Missing 18 20
 pT-stage 0.27 0.03
  T 0–2 106 (18.7%) 87 (19.7%) 19 (15.3%) 82 (13.7%) 69 (15.4%) 13 (8.5%)
  T 3–4 460 (81.3%) 355 (80.3%) 105 (84.7%) 518 (86.3%) 378 (84.6%) 140 (91.5%)
  Missing 14 56
 Nodal status 
primary 
tumor
0.86 0.98
  N0 260 (45.4%) 202 (45.3%) 58 (45.7%) 226 (35.2%) 167 (35.0%) 59 (35.8%)
  N1 214 (37.3%) 165 (37.0%) 49 (38.6%) 249 (38.8%) 186 (39.0%) 63 (38.2%)
  N2 99 (17.3%) 79 (17.7%) 20 (15.7%) 167 (26.0%) 124 (26.0%) 43 (26.1%)
  Missing 7 14
Colorectal liver 
metastases
 Synchronicity 0.62 0.20
  Synchonous 205 (35.3%) 157 (34.8%) 48 (37.2%) 487 (74.2%) 356 (73.0%) 131 (78.0%)
  Metachro-
nous
375 (64.7%) 294 (65.2%) 81 (62.8%) 169 (25.8%) 132 (27.0%) 37 (22.0%)
 Disease free 
interval
0.27 0.85
  ≤ 12 months 301 (52.0%) 240 (53.2%) 67 (52.3%) 547 (83.8%) 408 (83.6%) 139 (84.2%)
  > 12 months 278 (48.0%) 211 (46.8%) 61 (47.7%) 106 (16.2%) 80 (16.4%) 26 (15.8%)
  Missing 1 3
 Number 
CRLM
0.58 0.18
  1 334 (57.9%) 257 (57.4%) 77 (59.7%) 208 (32.0%) 156 (32.4%) 52 (31.1%)
  2 123 (21.3%0 95 (21.2%) 28 (21.7%) 124 (19.1%) 101 (21.0%) 23 (13.8%)
  3 68 (11.8%) 55 (12.3%) 13 (10.1%) 87 (13.4%) 66 (13.7%) 21 (12.6%)
  4 31 (5.4%) 27 (6.0%) 4 (3.1%) 78 (12.0%) 56 (11.6%) 22 (13.2%)
  5–9 17 (2.9%) 11 (2.5%) 6 (4.7%) 134 (20.6%) 92 (19.1%) 42 (25.1%)
  ≥ 10 4 (0.7%) 3 (0.7%) 3 (0.7%) 18 (2.8%) 11 (2.3%) 7 (4.2%)
  Missing 2 3
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Overall survival and HGPs
Patients with dHGP had a 5-year OS of 63.4% (95% CI 
57.7%–69.7%) compared to 45.9% (95% CI 42.6%–49.5%) 
in patients with non-dHGP (p < 0.001) (Appendix Fig. 4). In 
multivariable analysis, including the whole cohort, HGP was 
an independent predictor for OS (adjusted HR 1.57, 95% CI 
1.29–1.92, p = 0.008) (Appendix Table 3).
Table 1  (continued)
Not pretreated Pretreated
All patients No adjuvant 
CTx
Adjuvant CTx P value All patients No adjuvant 
CTx
Adjuvant CTx P value
 Size largest 
tumor
0.30 0.49
  ≤ 5 cm 451 (80.0%) 352 (80.9%) 99 (76.6%) 542 (84.0%) 407 (84.7%) 135 (82.3%)
  > 5 cm 113 (20.0%) 83 (19.1%) 30 (23.3%) 103 (16.0%) 74 (15.4%) 29 (17.7%)
  Missing 16 11
 Preoperative 
CEA
0.81 0.84
  ≤ 200 µg/L 521 (94.6%) 409 (94.7%) 112 (94.1%) 546 (89.8%) 403 (90.0%) 143 (89.4%)
  > 200 µg/L 30 (5.4%) 23 (5.3%) 7 (5.9%) 62 (10.2%) 45 (10.0%) 17 (10.6%)
  Missing 29 48
 Clinical risk 
score
0.44 0.93
  0–2 429 (76.1%) 333 (75.3%) 96 (78.7%) 311 (50.0%) 230 (49.9%) 81 (50.3%)
  3–5 135 (23.9%) 109 (24.7%) 26 (21.3%) 311 (50.0%) 231 (50.1%) 80 (49.7%)
  Missing 16 34
 Resection 
margin 
involved
0.50 0.47
  Yes 69 (11.9%) 60 (13.4%) 9 (7.0%) 118 (18.0%) 91 (18.7%) 27 (16.2%)
  No 509 (88.1%) 389 (86.6%) 120 (93.0%) 536 (82.0%) 396 (81.3%) 140 (83.8%)
 Tumor abla-
tion at time 
of resection
0.54 0.85
  Yes 48 (8.3%) 39 (8.6%) 9 (7.0%) 204 (31.1%) 153 (31.4%) 51 (30.5%)
  No 532 (91.7%) 412 (91.4%) 120 (93.0%) 451 (68.9%) 335 (68.6%) 116 (69.5%)
  Missing 0 1
 CTx regimen 
(pre/postop-
erative)
 < 0.001 0.82
  Oxaliplatin/
irinotecan 
based
85 (15.5%) 0 85 (82.5%) 579 (96.5%) 421 (96.5%) 158 (96.3%)
  5-FU based 18 (3.3%) 0 18 (17.5%) 21 (3.5%) 15 (3.4%) 6 (3.7%)
  No CTx 450 (81.4%) 450 (100%) 0
  Missing 27 56
 HGP 0.15 0.75
  dHGP 91 (15.7%) 76 (16.9%) 15 (11.6%) 189 (28.8%) 139 (71.5%) 50 (29.8%)
  Non-dHGP 489 (84.3%) 375 (83.1%) 114 (88.4%) 467 (71.2%) 349 (28.5%) 118 (70.2%)
Erasmus MC Erasmus Medical Center, CEA carcinoembryonic antigen, cm centimeter, CRLM colorectal liver metastases, CTx chemotherapy, 
dHGP desmoplastic type histopathological growth pattern, HGP histopathological growth pattern, IQR inter quartile range, MSKCC Memorial 
Sloan Kettering Cancer Center, non-dHGP non-desmoplastic type histopathological growth pattern, pT-stage tumor-stage derived from pathol-
ogy report
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Adjuvant chemotherapy and HGPs in patients 
without pretreatment
Of all 1236 patients, 580 patients (46.9%) did not receive 
preoperative chemotherapy. Most of these patients origi-
nated from Erasmus MC (n = 377, 65.0%). Adjuvant CTx 
was administered in 129 patients (21.1%) of this subgroup. 
Five-year OS was 65.2% (95% CI 56.7%–74.9%) in patients 
treated with adjuvant CTx compared to 47.5% (95% CI 
42.9%–52.6%) in patients not treated with adjuvant CTx 
(p = 0.002) (Fig. 3a).
No difference in 5-year OS was observed in dHGP 
patients treated with adjuvant CTx compared to patients not 
treated with adjuvant CTx (p = 0.17) (Fig. 3b). A 5-year OS 
(Fig. 3c) of 64.9% (95% CI 55.8%–75.5%) was observed 
in non-dHGP patients treated with adjuvant CTx compared 
40.3% (95% CI 35.3%–45.9%) in patients not treated with 
adjuvant CTx (p < 0.001).
In multivariable analysis (Table 2) adjuvant systemic CTx 
was associated with a superior OS in non-dHGP patients 
(adjusted HR 0.52, 95% CI 0.37–0.72, p < 0.001), but not 
in dHGP patients (adjusted HR 1.78, 95% CI 0.75–4.21, 
p = 0.19) (Appendix Table 4).
Adjuvant systemic chemotherapy and HGPs 
in patients with pretreatment
A total of 656 patients (53.1%) patients received preopera-
tive chemotherapy, of which 352 originated from MSKCC 
(53.7%). Adjuvant CTx was administered in 168 patients 
(25.6%) of patients who were pretreated prior to surgery. 
Five-year OS was 52.2% (95% CI 44.4%–61.3%) in patients 
treated with adjuvant CTx compared to 47.6% (95% CI 
43.1%–52.7%) in patients not treated with adjuvant CTx 
(p = 0.15) (Fig. 3d).
No difference in 5-year OS was observed in dHGP and 
non-dHGP patients treated with adjuvant CTx compared 
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Fig. 3  Kaplan–Meier of overall survival. Patients treated with adju-
vant CTx were compared to patients not treated with adjuvant CTx in 
the population of patients that were not pretreated (a–c). The follow-
ing populations were evaluated: a total patient cohort not pretreated, 
b dHGP patients not pretreated, and c non-dHGP patients not pre-
treated. Furthermore, patients treated with adjuvant CTx were com-
pared to patients not treated with adjuvant CTx in the population of 
patients that were pretreated (d–f). The following populations were 
evaluated: d total patient cohort pretreated, e dHGP patients pre-
treated, and f non-dHGP patients pretreated
599Clinical & Experimental Metastasis (2020) 37:593–605 
1 3
to patients not treated with adjuvant CTx (p = 0.50 and 
p = 0.19) (Fig. 3e and f). In multivariable analysis adjuvant 
CTx was not associated with OS in dHGP patients (adjusted 
HR 0.83, 95% CI 0.49–1.42, p = 0.50), nor in non-dHGP 
patients (adjusted HR 0.96, 95% CI 0.71–1.29, p = 0.79) 
(Appendix Table 5).
Disease‑free survival and HGPs
A superior 5-year DFS of 35.7% was found for patients with 
a dHGP compared to 18.7% in patients with a non-dHGP 
(p < 0.001). HGP was an independent factor for DFS in mul-
tivariable analysis (adjusted HR non-dHGP 1.52, 95% CI 
1.28–1.80, p < 0) (Appendix Table 6).
Superior 5-year DFS with adjuvant systemic treatment 
was only observed in patients with a non-dHGP that were 
not pretreated (20.4% versus 10.1%, p < 0.001) (Appen-
dix Fig. 5c). This was confirmed in multivariable analysis 
(adjusted HR 0.71, 95% CI 0.55–0.93, p < 0.001) (Appendix 
Table 7 and 8).
Discussion
This study investigates whether histopathological growth 
patterns predict the effect of adjuvant systemic chemo-
therapy after resection of CRLM. The results suggest that 
HGPs, that are assessed after resection of CRLM, are associ-
ated with the effectiveness of adjuvant CTx. Adjuvant CTx 
seemed highly effective in non-dHGP patients that were not 
pretreated with chemotherapy, resulting in improved OS 
(adjusted HR 0.52, p < 0.001) and DFS (adjusted HR 0.71, 
p < 0.001). In dHGP patients and in non-dHGP patients pre-
treated with CTx, no beneficial effect of adjuvant CTx could 
be demonstrated. Thereby, this study suggests that HGPs can 
be used to select patients for adjuvant CTx.
In order to determine the effectiveness of perioperative 
chemotherapy, several studies have been performed [1–5]. 
A large randomized trial evaluated the effectiveness of 
perioperative FOLFOX in patients with resectable CRLM 
(EORTC 40,983) [1]. Although this study was not powered 
on OS, and OS was not the primary endpoint of the study, no 
significant OS benefit was found after long-term follow-up 
[5]. Several non-randomized studies found that subgroups of 
patients may benefit from additional treatment with chemo-
therapy. These studies suggest that (neo-)adjuvant systemic 
chemotherapy might improve OS in patients at high risk of 
recurrence (i.e. aggressive tumor biology) [6, 7]. Post hoc 
analysis of the EORTC 40,983 trial demonstrated beneficial 
progression free survival in patients with elevated preop-
erative CEA levels (> 5 ng/ml) [15]. Furthermore, multiple 
previous studies have shown that the survival of patients 
with non-dHGP tumors is worse [11, 12, 16, 17]. Also, non-
dHGP (and especially the replacement-type of growth) is 
associated with several aggressive biological characteristics 
such as high histological grade, lack of inflammation, and 
increased cancer cell motility [11, 12, 16, 17]. Therefore, the 
observed higher effectiveness of adjuvant CTx in patients 
with non-dHGP, i.e. more aggressive tumors, is in line with 
previous research, although validation of these findings is 
needed. Biological explanations of why only patients with 
non-dHGP appear to benefit from adjuvant CTx are lacking.
A previous study suggests that the HGPs are a strong 
prognostic factor in patients who are not pretreated, and in 
pretreated patients the prognostic value was less [10]. This 
observation led to the analyses of the current study. In pre-
treated patients HGP was not suitable to identify patients 
that benefit from adjuvant CTx. Previously we observed a 
higher proportion of dHGP (30% vs 19%, p < 0.001) after 
preoperative chemotherapy, suggesting a potential conver-
sion to dHGP after pretreatment [10]. All in all, we believe 
that preoperative chemotherapy importantly changes HGPs. 
This could very well explain why the effect of HGPs on 
the effectiveness of adjuvant chemotherapy could only 
be demonstrated in those who were not pre-treated with 
chemotherapy.
Remarkably, we found that adjuvant CTx was not ben-
eficial at all in pretreated patients. This observation was 
independent for the HGP type. Similar observations were 
reported in previous studies, suggesting that pre- and 
Table 2  Uni- and multivariable 
Cox regression analysis for 
overall survival in non-dHGP 
patients (not pretreated) 
(n = 489)
CI confidence interval, CTx chemotherapy, non-dHGP non-desmoplastic type histopathological growth 
pattern, HR hazard ratio, R1 resection positive resection margin
Covariate Univariable Multivariable
HR 95% CI P value HR 95% CI P value
Non-dHGP
 Age at resection 1.02 1.01–1.03 0.006 1.02 1.01–1.03 0.006
 Right–sided primary tuimor 1.27 0.97–1.66 0.08 1.36 1.03–1.80 0.03
 Clinical risk score (3–5) 1.72 1.34–2.23  < 0.001 1.85 1.43–2.41  < 0.001
 R1 resection 1.37 1.00–1.88 0.05 1.21 0.86–1.70 0.28
 Adjuvant CTx 0.53 0.39–0.73  < 0.001 0.52 0.37–0.73  < 0.001
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postoperative chemotherapy is not superior to pre- or post-
operative chemotherapy alone [18, 19]. Explanations for this 
observation remain hypothetical, especially in the field of 
metastasized colorectal cancer. In colorectal cancer, it has 
been suggested that adjuvant chemotherapeutical regimes of 
only 3 months are as effective as 6 months [20]. This may 
also have been the case in the current study. Unfortunately, 
we could confirm this hypothesis since the number of cycles 
administered was unknown.
One could hypothesize that preoperative chemotherapy 
may be able to eliminate (extra)hepatic micrometastases. 
In that case, additional chemotherapy after surgery might 
be unnecessary. In patients that were not pretreated, addi-
tional postoperative chemotherapy may be able to eliminate 
the remaining micrometastatic disease. After all, it seems 
that timing of chemotherapy is not crucial. Chemotherapy 
administered at any time pre- or postoperative may be ben-
eficial in patients with upfront resectable CRLM.
However, adjuvant administration of chemotherapy in 
patients with upfront resectable CRLM may have several 
practical advantages compared to preoperative administra-
tion of chemotherapy. First, the normal liver parenchyma is 
not affected by chemotherapy prior to surgery, thereby not 
affecting the regenerative ability of the liver after resection. 
Also, the HGP can be assessed unambiguously after surgery, 
without the toxic effects on tumor cells and normal liver 
parenchyma. Adjuvant chemotherapy may also adhere to 
expectations of patients that prefer upfront surgery without 
postponement surgery by preoperative chemotherapy.
It should be noticed that the cohort of the current study 
comprised of initially borderline and upfront resectable 
CRLM that were treated with preoperative chemotherapy. 
In case of borderline resectable CRLM, administration of 
preoperative chemotherapy is obvious.
The results of this study should be interpreted in the light 
of several limitations. Most importantly, the non-randomized 
retrospective nature of this study. Some unidentified factors 
may have accounted for an unknown heterogeneity among 
the groups. In addition, the majority of patients treated with 
adjuvant CTx originated from MSKCC (over 95% in both 
groups). In the Erasmus MC Cancer Institute, no standard 
adjuvant CTx is given, according to the national guide-
lines. However, as discussed, no major significant differ-
ences were found at baseline. Furthermore, 5-year OS in 
patients not treated with adjuvant CTx from MSKCC and 
Erasmus MC was not statistically significant (49.1% ver-
sus 46.4%, p = 0.65), supporting that there are no differ-
ences in patient-outcome at baseline. Another factor that 
could have introduced unaccounted bias is the fact that 
in some patients resection was combined with ablation of 
one or more lesions. In some patients the HGP type could 
be misinterpreted, however this is probably limited since 
our previous study demonstrated a very high concordance 
of > 90% between metastases (in case of multiple CRLM in 
one patient) [14].
This is the first study that demonstrates the predictive 
value of HGPs for adjuvant CTx after resection of CRLM. 
HGPs are an easily available, affordable and reliable method 
for clinicians to gather additional information. Other studies 
are needed to confirm our findings. Moreover, randomized 
controlled trials investigating the effectiveness of adjuvant 
CTx might consider HGPs as a stratification factor in the 
analysis.
In conclusion, the current study suggests that HGPs are 
associated with the effectiveness of adjuvant CTx after 
resection of CRLM. Patients with non-dHGP seem more 
likely to benefit from adjuvant CTx, while patients with 
dHGP do not. After pre-operative chemotherapy, adjuvant 
chemotherapy seems of no further benefit, irrespective of 
HGP. Clinicians may consider both the HGP and prior chem-
otherapy as factors to guide the decision for adjuvant CTx 
after resection of CRLM.
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Table 3  Uni- and multivariable 
Cox regression analysis for 
overall survival (n = 1236)
CI confidence interval, CTx chemotherapy, dHGP desmoplastic type histopathological growth pattern, HR 
hazard ratio, R1 resection positive resection margin
Covariate Univariable Multivariable
HR 95% CI P value HR 95% CI P value
Age at resection 1.02 1.01–1.02  < 0.001 1.02 1.01–1.03  < 0.001
Right-sided primary tumor 1.33 1.12–1.59 0.001 1.27 1.06–1.52 0.01
Clinical risk score (3–5) 1.59 1.37–1.85  < 0.001 1.64 1.39–1.93  < 0.001
R1 resection 1.48 1.22–1.79  < 0.001 1.32 1.07–1.62 0.008
Preoperative CTx 1.11 0.96–1.28 0.17 1.12 0.95–1.32 0.17
Adjuvant CTx 1.35 1.12–1.62 0.002 0.77 0.63–0.93  < 0.001
Non-dHGP 1.54 1.28–1.86  < 0.001 1.57 1.29–1.92 0.008
Table 4  Uni- and multivariable 
Cox regression analysis for 
overall survival in dHGP 
patients (not pretreated) (n = 91)
CI confidence interval, CTx chemotherapy, dHGP desmoplastic type histopathological growth pattern, HR 
hazard ratio, R1 resection positive resection margin
Covariate Univariable Multivariable
HR 95% CI P value HR 95% CI P value
dHGP
 Age at resection 1.06 1.03–1.10  < 0.001 1.04 1.00–1.08 0.03
 Right-sided CRC 4.35 2.17–8.74  < 0.001 3.93 1.67–9.27 0.002
 Clinical risk score (3–5) 2.42 1.13–5.18 0.02 4.01 1.72–9.37 0.001
 R1 resection 1.56 0.47–5.12 0.47 2.23 0.50–9.95 0.29
 Adjuvant CTx 1.66 0.78–3.57 0.19 1.78 0.75–4.21 0.19
Table 5  Uni- and multivariable 
Cox regression analysis for 
overall survival in dHGP and 
non-dHGP patients (pretreated) 
(dHGP: n = 489; non-dHGP: 
n = 467)
CI confidence interval, CTx chemotherapy, dHGP desmoplastic type histopathological growth pattern, 
non-dHGP non-desmoplastic type histopathological growth pattern, HR hazard ratio, R1 resection positive 
resection margin
Covariate Univariable Multivariable
HR 95% CI P value HR 95% CI P value
dHGP
 Age at resection 1.01 0.99–1.03 0.19 1.02 1.00–1.04 0.10
 Right-sided CRC 1.21 0.73–1.99 0.46 1.17 0.70–1.95 0.56
 Clinical risk score (3–5) 1.22 0.80–1.86 0.35 1.39 0.89–2.16 0.15
 R1 resection 1.15 0.64–2.07 0.64 1.21 0.65–2.25 0.54
 Adjuvant CTx 0.85 0.52–1.38 0.50 0.83 0.49–1.42 0.50
Non-dHGP
 Age at resection 1.02 1.01–1.03  < 0.001 1.02 1.01–1.03 0.003
 Right-sided CRC 1.96 0.90–1.58 0.22 1.09 0.82–1.47 0.55
 Clinical risk score (3–5) 1.53 1.21–1.95  < 0.001 1.48 1.16–1.89 0.002
 R1 resection 1.48 1.13–1.94 0.005 1.38 1.04–1.85 0.03
 Adjuvant CTx 0.83 0.63–1.10 0.19 0.96 0.71–1.29 0.79
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Table 6  Uni- and multivariable 
Cox regression analysis for 
disease-free survival (n = 1236)
CI confidence interval, CTx chemotherapy, non-dHGP non-desmoplastic type histopathological growth 
pattern, HR hazard ratio, R1 resection positive resection margin
Covariate Univariable Multivariable
HR 95% CI P value HR 95% CI P value
Age at resection 1.00 0.99–1.01 0.90 1.00 1.00–1.01 0.28
Right-sided primary tumor 1.01 0.86–1.18 0.94 0.99 0.85–1.17 0.94
Clinical risk score (3–5) 1.61 1.41–1.84  < 0.001 1.54 1.34–1.77  < 0.001
R1 resection 1.41 1.19–1.68  < 0.001 1.33 1.11–1.59 0.002
Preoperative CTx 1.22 1.08–1.39 0.02 1.18 1.03–1.37 1.18
Adjuvant CTx 1.11 0.96–1.29 0.17 0.95 0.81–1.11 0.50
Non-dHGP 1.41 1.20–1.66  < 0.001 1.52 1.28–1.80  < 0.001
Table 7  Uni- and multivariable 
Cox regression analysis for 
disease-free survival in dHGP 
and non-dHGP patients (not 
pretreated)(dHGP n = 91, non-
dHGP: n = 489)
CI confidence interval, CTx chemotherapy, dHGP desmoplastic type histopathological growth pattern, 
non-dHGP non-desmoplastic type histopathological growth pattern, HR hazard ratio, R1 resection positive 
resection margin
Covariate Univariable Multivariable
HR 95% CI P value HR 95% CI P value
dHGP
 Age at resection 1.01 0.99–1.04 0.31 1.01 0.98–1.04 0.47
 Right-sided CRC 1.61 0.86–3.03 0.14 1.55 0.76–3.17 0.23
 Clinical risk score (3–5) 2.26 1.46–4.44 0.02 2.62 1.29–5.34 0.008
 R1 resection 2.00 0.79–5.10 0.15 2.63 0.88–7.84 0.08
 Adjuvant CTx 0.62 0.40–1.72 0.91 0.41–2.01 0.82
Non-dHGP
 Age at resection 1.00 0.99–1.01 0.47 1.01 0.99–1.02 0.40
 Right-sided CRC 0.94 0.74–1.20 0.61 1.00 0.77–1.28 0.98
 Clinical risk score (3–5) 1.62 1029–2.04  < 0.001 1.63 1.29–2.05  < 0.001
 R1 resection 1.35 1.01–1.81 0.04 1.32 0.97–1.79 0.08
 Adjuvant CTx 0.68 0.53–0.87 0.002 0.71 0.55–0.93 0.01
Table 8  Uni- and multivariable 
Cox regression analysis for 
disease-free in dHGP and 
non-dHGP patients (pretreated) 
(dHGP: n = 489; non-dHGP: 
n = 467)
CI confidence interval, CTx chemotherapy, dHGP desmoplastic type histopathological growth pattern, 
non-dHGP non-desmoplastic type histopathological growth pattern, HR hazard ratio, R1 resection positive 
resection margin
Covariate Univariable Multivariable
HR 95% CI P value HR 95% CI P value
dHGP
 Age at resection 1.00 0.99–1.02 0.70 1.01 0.99–1.03 0.36
 Right-sided CRC 1.09 0.72–1.65 0.69 1.09 0.71–1.67 0.71
 Clinical risk score (3–5) 1.46 1.02–2.10 0.04 1.50 1.03–2.19 0.03
 R1 resection 1.33 0.80–2.19 0.27 1.26 0.74–2.16 0.40
 Adjuvant CTx 1.17 0.80–1.72 0.42 1.20 0.80–1.81 0.38
Non-dHGP
 Age at resection 0.97 0.99–1.01 0.97 1.00 0.99–1.01 0.88
 Right-sided CRC 0.98 0.77–1.25 0.87 0.94 0.73–1.22 0.66
 Clinical risk score (3–5) 1.49 1.21–1.83  < 0.001 1.46 1.18–1.80  < 0.001
 R1 resection 1.28 1.01–1.63 0.05 1.31 1.02–1.69 0.04
 Adjuvant CTx 1.05 0.84–1.32 0.65 1.13 0.88–1.44 0.34
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Fig. 4  Kaplan–Meier of overall survival stratified by HGP
Fig. 5  Kaplan–Meier of disease-free survival. Patients treated with 
adjuvant CTx were compared to patients not treated with adjuvant 
CTx in the population of patients that were not pretreated (a–c). The 
following populations were evaluated: a total patient cohort not pre-
treated, b dHGP patients not pretreated, and c non-dHGP patients 
not pretreated. Furthermore, patients treated with adjuvant CTx were 
compared to patients not treated with adjuvant CTx in the population 
of patients that were pretreated (d–f). The following populations were 
evaluated: d total patient cohort pretreated, e dHGP patients pre-
treated, and f non-dHGP patients pretreated
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